Alendronate is the generic name for Fosamax. It is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone [1].
What is Alendronate used for?
Alendronate is prescribed to prevent and treat bone loss in women after menopause, and in men and women with low bone density or certain medical conditions. It works by slowing down bone loss, which helps maintain bone strength and reduces the risk of fractures [1][2].
How long does Alendronate take to work?
The effects of alendronate on bone mineral density may not be apparent for several months. Consistent use is necessary to see the full benefits of the medication [2].
What are the side effects of Alendronate?
Common side effects include heartburn, difficulty swallowing, and irritation of the esophagus. More serious, though rare, side effects can include jaw bone problems (osteonecrosis of the jaw), thigh bone fractures, and stomach ulcers [2][3]. Patients should seek medical attention if they experience severe pain in the jaw or thigh, or if they have trouble swallowing or persistent heartburn [3].
How should Alendronate be taken?
Alendronate should be taken on an empty stomach first thing in the morning with a full glass of plain water. Patients should remain upright for at least 30 minutes after taking the medication and for at least 30 minutes after their first food of the day. This is to help prevent irritation of the esophagus [2].
Are there alternatives to Alendronate?
Yes, other bisphosphonates, such as risedronate (Actonel) and ibandronate (Boniva), are available. Other treatment options for osteoporosis include denosumab (Prolia), teriparatide (Forteo), and raloxifene (Evista), each with different mechanisms of action and administration routes [4].
When does the patent for Fosamax expire?
The primary patents for Fosamax have long since expired, allowing for the availability of generic alendronate [5]. DrugPatentWatch.com tracks patent information for medications, and for Fosamax (alendronate), key patents have expired, leading to generic competition [5].